Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Jazz Pharma
Jazz Pharma
Jazz to search for new chief as CEO plans retirement
BioPharma Dive
Mon, 12/16/24 - 11:15 pm
Jazz Pharma
Pharma CEOs
Bruce Cozadd
Jazz's HER2 bispecific snags FDA nod, teeing up showdown with AZ and Daiichi's Enhertu
Fierce Pharma
Thu, 11/21/24 - 11:18 am
Jazz Pharma
FDA
HER2 Inhibitor
bispecifics
zanidatamab
Jazz's almost-withdrawn lung cancer drug Zepzelca extends life on top of Roche’s Tecentriq
Fierce Pharma
Tue, 10/15/24 - 11:03 am
Jazz Pharma
Zepzelca
extensive-stage small cell lung cancer
Roche
Tecentriq
ESMO: Jazz HER2 bispecific posts 59% survival at 30 months in gastric cancer
Fierce Biotech
Mon, 09/16/24 - 09:50 am
Jazz Pharma
zanidatamab
gastroesophageal cancer
ESMO
Jazz, Hikma must face 'reverse payment' claims over narcolepsy drug
Reuters
Tue, 08/27/24 - 10:32 pm
Jazz Pharma
Hikma
Xyrem
reverse payments
legal
Jazz’s cannabidiol therapy flunks in Japanese Phase III trial
Clinical Trials Arena
Fri, 08/23/24 - 10:47 am
Jazz Pharma
Cannabidiol
Japan
Epidiolex
Jazz hits dud note as midphase essential tremor test misses endpoint
Fierce Biotech
Thu, 06/20/24 - 11:36 am
Jazz Pharma
essential tremors
clinical trials
suvecaltamide
Alkermes and Jazz: Two Different Approaches to Neuroscience, Oncology Portfolios
BioSpace
Tue, 03/12/24 - 11:02 am
Alkermes
Jazz Pharma
Neuroscience
oncology
Jazz buys KRAS inhibitors from Redx in $880m deal
Pharmaphorum
Wed, 02/7/24 - 11:18 am
Jazz Pharma
Redx Pharma
KRAS inhibitors
oncology
Jazz drops PTSD drug over phase 2 trial failure
Fierce Biotech
Fri, 12/22/23 - 09:39 am
Jazz Pharma
PTSD
FAAH inhibitors
clinical trials
JZP150
How this CEO Built A Top 50 Pharma Company Focusing On Culture Day 1
Forbes
Wed, 12/6/23 - 12:00 am
Jazz Pharma
Bruce Cozadd
Jazz halts sleep disorder med trial over 'visual disturbances' and CV effects
Fierce Biotech
Wed, 11/29/23 - 11:50 am
Jazz Pharma
phase 1 sleep disorder
Sumitomo Pharma
JZP441
Autifony swings $770.5m deal with Jazz for CNS drugs
Pharmaphorum
Tue, 11/14/23 - 09:22 am
Autifony
Jazz Pharma
neurological disorders
Jazz looks at strategic options, including possible sale or unit divestiture
Fierce Pharma
Fri, 10/20/23 - 11:58 am
Jazz Pharma
Xyrem
M&A
6 Drugs Approved Despite Failed Trials or Minimal Data
BioSpace
Mon, 10/9/23 - 11:10 am
Ipsen
Sohonos
Sarepta Therapeutics
Elevidys
Biogen
Qalsody
Eisai
Aduhelm
Jazz Pharma
PharmaMar
Zepzelca
Acadia Pharma
Nuplazid
Jazz Pharma sues FDA over approval of rival narcolepsy drug
Medical Marketing and Media
Tue, 06/27/23 - 11:29 am
Jazz Pharma
FDA
Xyrem
Avadel Pharma
Lumryz
legal
With FDA nod for Lumryz, Avadel is set to Jazz up the narcolepsy market
Fierce Pharma
Tue, 05/2/23 - 11:41 am
Avadel Pharma
Jazz Pharma
Lumryz
Xyrem
narcolepsy
Jazz loses appeal, will have patent delisted from the Orange Book
Endpoints
Mon, 02/27/23 - 07:09 pm
Jazz Pharma
Orange Book
narcolepsy
generics
legal
Jazz sues generics makers for infringement on cannabis-derived epilepsy drug
Fierce Pharma
Thu, 01/5/23 - 05:00 pm
Jazz Pharma
legal
cannabindoids
Epidiolex
generics
patents
Jazz hands Zymeworks a much-needed win for biliary tract cancer drug after peek at data
Fierce Biotech
Wed, 12/21/22 - 11:24 am
Zymeworks
Jazz Pharma
biliary tract cancer
zanidatamab
Pages
1
2
3
next ›
last »